Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Jan 14, 2022 9:42am
69 Views
Post# 34316335

RE:RE:RepliCel Announces Material Patent Milestones

RE:RE:RepliCel Announces Material Patent MilestonesHi,
Agree  that  volume is super low and seems that stock has been forgotten.   Does anyone know  what the  control situation is?

Given  the relatively low number of shares out  , it is a bit of a double edged sword.  Not enough shares to allow  a good market  yet  low enough that if something good comes out it could 'pop'  big time very quickly.

very happy that we have not been deluged with  a ton of dilution over the years.  My hope is that it will  'fly'  this year  as I  have been here for quite a while  and  am in at over  $1  per share.  At this point  its hard for me to average down  to any number close to todays price without  tying up a lot of money.  Then  comes  if  I can even  buy that many  shares  without  pumping the price.

Guess it is  wait and hope  this year  'IS THE YEAR'

GLTA
<< Previous
Bullboard Posts
Next >>